C-Reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery

Anticancer Research

Volumn 33, Issue 11, 2013, Pages 5065-5074

  Toiyama, Yuji ^a   Inoue, Yasuhiro ^a   Saigusa, Susumu ^a   Kawamura, Mikio ^a   Kawamoto, Aya ^a   Okugawa, Yoshinaga ^a   Hiro, Jyunichiro ^a   Tanaka, Koji ^a   Mohri, Yasuhiko ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

C Reactive protein; Chemoradiotherapy; Neutrophil lymphocyte ratio; Platelet lymphocyte ratio; Prognosis; Rectal cancer

Indexed keywords

C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; UFT;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURGERY; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPHOCYTE; MALE; MIDDLE AGED; NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; RECTUM CANCER; THROMBOCYTE; TREATMENT RESPONSE;

C-REACTIVE PROTEIN; CHEMORADIOTHERAPY; NEUTROPHIL/LYMPHOCYTE RATIO; PLATELET/LYMPHOCYTE RATIO; PROGNOSIS; RECTAL CANCER;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; C-REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SIGNET RING CELL; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEUTROPHILS; PROGNOSIS; RECTAL NEOPLASMS; SURVIVAL RATE; TEGAFUR; TUMOR MARKERS, BIOLOGICAL; URACIL;

EID: 84891363853     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H and Raab R: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731-1740, 2004.
2. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A and Ollier JC: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355: 1114-1123, 2006.
3. Akiyoshi T, Kobunai T and Watanabe T: Recent approaches to identifying biomarkers for high-risk stage II colon cancer. Surg Today 42: 1037-1045, 2012.
4. Kelley RK and Venook AP: Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer 10: 73-80, 2011.
5. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS and Ogino S: Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 222: 350-366, 2010.
6. Roxburgh CS and McMillan DC: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6: 149-163, 2010.
7. McMillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12: 223-226, 2009.
8. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC: A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47: 2633-2641, 2011.
9. Roxburgh CS, Salmond JM, Horgan PG, Oien KA and McMillan DC: Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 249: 788-793, 2009.
10. McMillan DC, Crozier JE, Canna K, Angerson WJ and McArdle CS: Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22: 881-886, 2007.
11. Roxburgh C, McDonald A, Salmond J, Oien K, Anderson J, McKee R, Horgan P and McMillan D: Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors. Int J Colorectal Dis 26: 483-492, 2011.
12. Ishizuka M, Nagata H, Takagi K and Kubota K: Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Ann Surg 250: 268-272, 2009.
13. Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC: An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 104: 726-734, 2011.
14. Walsh SR, Cook EJ, Goulder F, Justin TA and Keeling NJ: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91: 181-184, 2005.
15. Malik HZ, Prasad KR, Halazun KJ, Aldoori A, Al-Mukhtar A, Gomez D, Lodge JP and Toogood GJ: Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg 246: 806-814, 2007.
16. Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, Wan DS and Pan ZZ: Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 25: 1427-1433, 2010.
17. Sobin LH, Gospodarowicz MK and Wittekind C: UICC: TNM classification of malignant tumors. 7th ed. Oxford: Wiley-Blackwell, 2009.
18. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T and Hashimoto-Tamaoki T: Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61: 1029-1037, 2001.
19. Chiang SF, Hung HY, Tang R, Changchien CR, Chen JS, You YT, Chiang JM and Lin JR: Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively? Int J Colorectal Dis 27: 1347-1357, 2012.
20. Japanese Society for Cancer of the Colon and Rectum: General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. Tokyo, Kanehara, 2006.
21. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R and Wittekind C: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23: 8688-8696, 2005.
22. Bujko K, Michalski W, Kepka L, Nowacki MP, Nasierowska-Guttmejer A, Tokar P, Dymecki D, Pawlak M, Lesniak T, Richter P, Wojnar A and Chmielik E: Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys 67: 369-377, 2007.
23. Kim NK, Baik SH, Seong JS, Kim H, Roh JK, Lee KY, Sohn SK and Cho CH: Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival. Ann Surg 244: 1024-1030, 2006.
24. Kim TH, Chang HJ, Kim DY, Jung KH, Hong YS, Kim SY, Park JW, Oh JH, Lim SB, Choi HS and Jeong SY: Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Int J Radiat Oncol Biol Phys 77: 1158-1165, 2010.
25. Huh JW, Kim CH, Kim HR and Kim YJ: Oncologic outcomes of pathologic stage I lower rectal cancer with or without preoperative chemoradiotherapy: are they comparable? Surgery 150: 980-984, 2011.
26. Nissan A, Stojadinovic A, Shia J, Hoos A, Guillem JG, Klimstra D, Cohen AM, Minsky BD, Paty PB and Wong WD: Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. J Clin Oncol 24: 4078-4084, 2006.
27. Park JW, Lim SB, Kim DY, Jung KH, Hong YS, Chang HJ, Choi HS and Jeong SY: Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery. Int J Radiat Oncol Biol Phys 74: 810-817, 2009.
28. Moreno Garcia V, Cejas P, Blanco Codesido M, Feliu Batlle J, de Castro Carpeno J, Belda-Iniesta C, Barriuso J, Sanchez JJ, Larrauri J, Gonzalez-Baron M and Casado E: Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Colorectal Dis 24: 741-748, 2009.
29. Perez RO, Sao Juliao GP, Habr-Gama A, Kiss D, Proscurshim I, Campos FG, Gama-Rodrigues JJ and Cecconello I: The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer. Dis Colon Rectum 52: 1137-1143, 2009.
30. Yasuda K, Sunami E, Kawai K, Nagawa H and Kitayama J: Laboratory blood data have a significant impact on tumor response and outcome in preoperative chemoradiotherapy for advanced rectal cancer. J Gastrointest Cancer 43: 236-243, 2012.
31. Kawai K, Kitayama J, Tsuno NH, Sunami E and Watanabe T: Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer. Int J Colorectal Dis 28: 527-535, 2013.
32. Carruthers R, Tho LM, Brown J, Kakumanu S, McCartney E and McDonald AC: Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer. Colorectal Dis 14: e701-707, 2012.
33. Kawai K, Kitayama J, Tsuno NH, Sunami E and Nagawa H: Hyperfibrinogenemia after preoperative chemoradiotherapy predicts poor response and poor prognosis in rectal cancer. Int J Colorectal Dis 26: 45-51, 2011.
34. Lu K, Zhu Y, Sheng L, Liu L, Shen L and Wei Q: Serum fibrinogen level predicts the therapeutic response and prognosis in patients with locally advanced rectal cancer. Hepatogastroenterology 58: 1507-1510, 2011.
35. MERCURY Study Group: Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 333: 779, 2006.
36. Low G, Tho LM, Leen E, Wiebe E, Kakumanu S, McDonald AC and Poon FW: The role of imaging in the preoperative staging and postoperative follow-up of rectal cancer. Surgeon 6: 222-231, 2008.
37. Bujko K, Glynne-Jones R and Bujko M: Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol 21: 1743-1750, 2010.